Cite
Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia
MLA
Valerie J. Whiterock, et al. “Triazolopyridine Ethers as Potent, Orally Active MGlu2 Positive Allosteric Modulators for Treating Schizophrenia.” Bioorganic & Medicinal Chemistry, vol. 25, Jan. 2017, pp. 496–513. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d4fbbfea4e7fe10fc6e8c858a57219bd&authtype=sso&custid=ns315887.
APA
Valerie J. Whiterock, Amy Easton, Regina Miller, Lawrence R. Marcin, Meredith Ferrante, Bradley C. Pearce, John B. Hogan, Joanne J. Bronson, Clotilde Bourin, Mendi A. Higgins, Robert G. Gentles, F. Christopher Zusi, Walter Kostich, John E. Macor, Michael Gulianello, Min Ding, Linda J. Bristow, Adam Hendricson, Kim A. Johnson, … Matthew A. Seager. (2017). Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia. Bioorganic & Medicinal Chemistry, 25, 496–513.
Chicago
Valerie J. Whiterock, Amy Easton, Regina Miller, Lawrence R. Marcin, Meredith Ferrante, Bradley C. Pearce, John B. Hogan, et al. 2017. “Triazolopyridine Ethers as Potent, Orally Active MGlu2 Positive Allosteric Modulators for Treating Schizophrenia.” Bioorganic & Medicinal Chemistry 25 (January): 496–513. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d4fbbfea4e7fe10fc6e8c858a57219bd&authtype=sso&custid=ns315887.